Statins and COVID-19: Are they each other indifferent?

Česká verzia

Authors: Jaroslav A. Hubáček ^1,2
Authors place of work: Centrum experimentální medicíny, Institut klinické a experimentální medicíny, Praha ¹; III. interní klinika – endokrinologie a metabolismu 1. LF UK a VFN v Praze ²
Published in the journal: AtheroRev 2021; 6(3): 127-130
Category: Reviews

Summary

COVID-19 (COronaVIrus Disease 2019) caused by the coronavirus SARS-CoV-2 infection has spread rapidly worldwide and, despite its relatively low mortality, is responsible for about 4 million deaths so far due to its high infectivity. Several interventions, whether prophylactic or symptomatic, are being retrospectively investigated. SARS-CoV-2 enters cells using two pathways, either through the ACE2 receptor or through lipid rafts. The function of both can be influenced by statins, first choice drugs to lower plasma cholesterol levels. Because ongoing statin therapy lowers not only plasma cholesterol, but also cholesterol levels in cell membranes and lipid rafts (their proper function depends on cholesterol availability) as well, statin therapy is discussed as COVID-19 treatment option. In opposite, however, experimental studies have shown that statins increase the concentration of ACE2 receptors – thus, statins could have also potential to facilitate virus entry into cells. Observational studies have not reached a clear conclusion either, mainly because statin treated individuals are usually older and polymorbid and it is not easy to separate the effects of all confounding factors. However, the largest metaanalysis (almost 12 000 000 subjects included) performed so far, has not associated statins with lower risk of disease, disease severity or mortality. Still, it is possible, that in some subgroups of patients (especially diabetics) concomitant use of statins could be profitable.

Keywords:

Cholesterol – statins – COVID-19

Zdroje

Coronaviridae Study Group of the International Committee on Taxonomy of Viruses. The species Severe acute respiratory syndrome-related coronavirus: classifying 2019-nCoV and naming it SARS-CoV-2. Nat Microbiol 2020; 5(4): 536–544. Dostupné z DOI: <http://doi 10.1038/s41564–020–0695-z>.
Liu YC, Kuo RL, Shih SR. COVID-19: The first documented coronavirus pandemic in history. Biomed J 2020; 43(4): 328–333. Dostupné z DOI: <http://doi 10.1016/j.bj.2020.04.007>.
Petrosillo N, Viceconte G, Ergonul O et al. COVID-19, SARS and MERS: are they closely related? Clin Microbiol Infect 2020; 26(6): 729–734. Dostupné z DOI: <http://doi 10.1016/j.cmi.2020.03.026>.
Hippisley-Cox J, Young D, Coupland C et al. Risk of severe COVID-19 disease with ACE inhibitors and angiotensin receptor blockers: cohort study including 8.3 million people. Heart 2020; 106(19): 1503–1511. Dostupné z DOI: <http://doi 10.1136/heartjnl-2020–317393>.
Purohit B, Panda AK. Smoking habits correlate with the defense against SARS-CoV-2 infection in the Indian population. Hum Cell 2021; 34(4): 1282–1284. Dostupné z DOI: Dostupné z DOI: <http://doi 10.1007/s13577–021–00552-w>.
Lassale C, Gaye B, Hamer M et al. Ethnic disparities in hospitalisation for COVID-19 in England: The role of socioeconomic factors, mental health, and inflammatory and pro-inflammatory factors in a community-based cohort study. Brain Behav Immun 2020; 88: 44–49. Dostupné z DOI: Dostupné z DOI: <http://doi 10.1016/j.bbi.2020.05.074>.
Hastie CE, Mackay DF, Ho F et al. Vitamin D concentrations and COVID-19 infection in UK Biobank. Diabetes Metab Syndr 2020; 14(4): 561–565. Dostupné z DOI: <http://doi 10.1016/j.dsx.2020.04.050>. Erratum in: Diabetes Metab Syndr 2020; 14(5): 1315–1316.
Rosenthal N, Cao Z, Gundrum J et al. Risk factors associated with in-hospital mortality in a US national sample of patients with COVID-19. JAMA Netw Open 2020; 3(12): e2029058. Dostupné z DOI: <http://doi 10.1001/jamanetworkopen.2020.29058>. Erratum in: JAMA Netw Open 2021; 4(1): e2036103.
Schade DS, Shey L, Eaton RP. Cholesterol review: A metabolically important molecule. Endocr Pract 2020; 26(12): 1514–1523. Dostupné z DOI: <http://doi 10.4158/EP-2020–0347>.
Kočar E, Režen T, Rozman D. Cholesterol, lipoproteins, and COVID-19: Basic concepts and clinical applications. Biochim Biophys Acta Mol Cell Biol Lipids 2021; 1866(2): 158849. Dostupné z DOI: <http://doi 10.1016/j.bbalip.2020.158849>.
Simons K, Ehehalt R. Cholesterol, lipid rafts, and disease. J Clin Invest 2002; 110(5): 597–603. Dostupné z DOI: <http://doi 10.1172/JCI16390>.
Li GM, Li YG, Yamate M et al. Lipid rafts play an important role in the early stage of severe acute respiratory syndrome-coronavirus life cycle. Microbes Infect 2007; 9(1): 96–102. Dostupné z DOI: <http://doi 10.1016/j.micinf.2006.10.015>.
Scialo F, Daniele A, Amato F et al. ACE2: the major cell entry receptor for SARS-CoV-2. Lung 2020; 198(6): 867–877. Dostupné z DOI: <http://doi 10.1007/s00408–020–00408–4>.
Wang H, Yuan Z, Pavel MA et al. The role of high cholesterol in age-related COVID19 lethality. Biorxiv 2021. Dostupné z DOI: <http://doi.org/10.1101/2020.05.09.086249>.
Tikoo K, Patel G, Kumar S et al. Tissue specific up regulation of ACE2 in rabbit model of atherosclerosis by atorvastatin: role of epigenetic histone modifications. Biochem Pharmacol 2015; 93(3): 343–51. Dostupné z DOI: <http://doi 10.1016/j.bcp.2014.11.013>.
Li YH, Wang QX, Zhou JW et al. Effects of rosuvastatin on expression of angiotensin-converting enzyme 2 after vascular balloon injury in rats. J Geriatr Cardiol 2013; 10(2): 151–158. Dostupné z DOI: <http://doi 10.3969/j.issn.1671–5411.2013.02.009>.
Wei X, Zeng W, Su J et al. Hypolipidemia is associated with the severity of COVID-19. J Clin Lipidol 2020; 14(3): 297–304. Dostupné z DOI: <http://doi 10.1016/j.jacl.2020.04.008>.
Fan J, Wang H, Ye G et al. Low-density lipoprotein is a potential predictor of poor prognosis in patients with coronavirus disease 2019. Metabolism 2020; 107: 154243. Dostupné z DOI: <http://doi 10.1016/j.metabol.2020.154243>.
Cariou B, Goronflot T, Rimbert A et al. Routine use of statins and increased COVID-19 related mortality in inpatients with type 2 diabetes: Results from the CORONADO study. Diabetes Metab 2021; 47(2): 101202. Dostupné z DOI: <http://doi 10.1016/j.diabet.2020.10.001>.
Mitacchione G, Schiavone M, Curnis A et al. Impact of prior statin use on clinical outcomes in COVID-19 patients: data from tertiary referral hospitals during COVID-19 pandemic in Italy. J Clin Lipidol 2021; 15(1): 68–78. Dostupné z DOI: <http://doi 10.1016/j.jacl.2020.12.008>.
Saeed O, Castagna F, Agalliu I et al. Statin use and in-hospital mortality in patients with diabetes mellitus and COVID-19. J Am Heart Assoc 2020; 9(24): e018475. Dostupné z DOI: <http://doi 10.1161/JAHA.120.018475>.
Gupta A, Madhavan MV, Poterucha TJ et al. Association between antecedent statin use and decreased mortality in hospitalized patients with COVID-19. Nat Commun 2021; 12(1): 1325. Dostupné z DOI: <http://doi 10.1038/s41467–021–21553–1>.
Torres-Peña JD, Pérez-Belmonte LM, Fuentes-Jiménez F et al. Prior treatment with statins is associated with improved outcomes of patients with COVID-19: Data from the SEMI-COVID-19 Registry. Drugs 2021; 81: 685–695. Dostupné z DOI: <http://doi 10.1007/s40265–021–01498-x>.
Zein AFMZ, Sulistiyana CS, Khasanah U et al. Statin and mortality in COVID-19: a systematic review and meta-analysis of pooled adjusted effect estimates from propensity-matched cohorts. Postgrad Med J 2021: postgradmedj-2021–140409. Dostupné z DOI: <http://doi 10.1136/postgradmedj-2021–140409>.
Kow CS, Hasan SS. Meta-analysis of effect of statins in patients with COVID-19. Am J Cardiol 2020; 134: 153–155. Dostupné z DOI: <http://doi 10.1016/j.amjcard.2020.08.004>.
Chow R, Im J, Chiu N et al. The protective association between statins use and adverse outcomes among COVID-19 patients: A systematic review and meta-analysis. PLoS One. 2021; 16(6): e0253576. Dostupné z DOI: <http://doi 10.1371/journal.pone.0253576>.
Hariyanto TI, Kurniawan A. Statin and outcomes of coronavirus disease 2019 (COVID-19): A systematic review, meta-analysis, and meta-regression. Nutr Metab Cardiovasc Dis 2021; 31(6): 1662–1670. Dostupné z DOI: <http://doi 10.1016/j.numecd.2021.02.020>.
Holman N, Knighton P, Kar P et al. Risk factors for COVID-19-related mortality in people with type 1 and type 2 diabetes in England: a population-based cohort study. Lancet Diabetes Endocrinol 2020; 8(10): 823–833. Dostupné z DOI: <http://doi 10.1016/S2213–8587(20)30271–0>.